|
|
Blood, Vol. 113, Issue 11, 2517-2525, March 12, 2009
Genetic variants in the candidate genes of the apoptosis pathway and susceptibility to chronic myeloid leukemia
Blood Kim et al.
113: 2517
Supplemental materials for: Kim et al
Files in this Data Supplement:
- Table S1. Primer Sequences for PCR amplification of each genotype (PDF, 37.7 KB)
- Table S2. Detailed information of single marker analysis for the susceptibility to chronic myeloid leukemia (PDF, 150 KB)
- Table S3. Result of permutation test based on additive model with or without adjustment for covariates (PDF, 79.4 KB)
- Table S4. Comparison of genotype frequency between on therapy versus de novo group (A), between control versus on therapy group (B), and between control versus on therapy group (C) (PDF, 139 KB) -
Here are the 2 by 2 Genotype frequency tables (with chi-square tests) to compare the groups (0) Control, (1) On therapy and (2) De Novo. Only Caucasian patients were included in this analysis.
- Table S5. Univariate logistic regression analysis in the subgroup (PDF, 65.2 KB)
- Figure S1. Comparison of complete cytogenetic response and major molecular response between On therapy and De novo group in CML cases (JPG, 66.4 KB)
-
* The treatment includes imatinib (n=170, 100%), interferon (n=34),and allogeneic stem cell transplantation (n=11). When we evaluate the incidence of complete cytogenetic or molecular response, no differences of treatment outcomes were observed between the de novo versus on therapy groups as shown in the below figures. The complete cytogenetic response rates in On therapy and De novo group were 70% vs 71% at 12 months (p=0.864), 78% vs 80% at 18 months (p=0.522), 80% vs 86% at 24 months (p=0.586) and 83% vs 93% at 36 months (p=0.320; above figure A). The major molecular response rates in On therapy and De novo group were 40% vs 35% at 12 months (p=0.478), 49% vs 54% at 18 months (p=0.627), 54% vs 71% at 24 months (p=0.104), and 69% vs 85% at 36 months (p=0.219; above figure B).
|
|
